Alastair Garfield
Chief Scientific OfficerDr. Alastair Garfield, also known as Al, Ph.D. is Chief Scientific Officer of Rhythm Pharmaceuticals, Inc. from July 1, 2024. He joined Rhythm Pharmaceuticals, Inc in July, 2024. Dr. Garfield rejoined Rhythm after serving as Senior Vice President and Head of Translational Sciences and Strategy at Rectify Pharma, where he helped deliver first-in-class therapeutics for rare disease. Prior to Rectify, Dr. Garfield was Senior Vice President and Head of Translational Research at Rhythm. He was an assistant professor at the University of Edinburgh, UK and visiting professor Harvard Medical School. He also held roles at Pfizer, where he was a lab head in the Cardiovascular Metabolic Disease Research Unit and led novel obesity target identification. He holds a first-class degree in molecular and cellular biology and a Ph.D. in molecular genetics from the University of Bath, UK. He has postdoctoral fellowships at the University of Cardiff, UK and University of Cambridge, UK focused on neural pathways and genes underlying mammalian energy balance.
Positions
- Company NameRhythm Pharmaceuticals, Inc.Stock CodeRYTMPositionChief Scientific OfficerColleagues
- DPDavid P. MeekerChairman, President & CEO
- HCHunter C. SmithCFO & Treasurer
- YMYann MazabraudExecutive VP & Head of International
- JLJennifer LeeExecutive VP & Head of North America
- DWDavid W. J. McGirrIndependent Director
- LMLee M. KaplanChairman of Scientific Advisory Board
- SAStuart A. ArbuckleIndependent Director
- LALynn A. TetraultIndependent Lead Director
